孔倩文, 刘慧峰, 王春艳, 卢燕敏. 基于目标心率调整倍他乐克剂量治疗冠心病的疗效观察[J]. 心脏杂志, 2020, 32(5): 490-492. DOI: 10.12125/j.chj.202006019
    引用本文: 孔倩文, 刘慧峰, 王春艳, 卢燕敏. 基于目标心率调整倍他乐克剂量治疗冠心病的疗效观察[J]. 心脏杂志, 2020, 32(5): 490-492. DOI: 10.12125/j.chj.202006019
    shu
    Qian-wen KONG, Hui-feng LIU, Chun-yan WANG, Yan-min LU. Efficacy of betaloc dose in treatment of coronary heart disease based on adjustment of target heart rate[J]. Chinese Heart Journal, 2020, 32(5): 490-492. DOI: 10.12125/j.chj.202006019
    Citation: Qian-wen KONG, Hui-feng LIU, Chun-yan WANG, Yan-min LU. Efficacy of betaloc dose in treatment of coronary heart disease based on adjustment of target heart rate[J]. Chinese Heart Journal, 2020, 32(5): 490-492. DOI: 10.12125/j.chj.202006019
    shu

    基于目标心率调整倍他乐克剂量治疗冠心病的疗效观察

    Efficacy of betaloc dose in treatment of coronary heart disease based on adjustment of target heart rate

      摘要
    • 摘要:
        目的  探讨以目标心率调整倍他乐克剂量治疗冠心病的治疗效果。
        方法  选取2018年6月至2019年12月在我院就诊的100例冠心病患者，随机分为目标剂量组和目标心率组，每组各50例。除其他固定的冠心病二级预防用药外，目标剂量组服用倍他乐克的剂量为逐步滴定至目标剂量（即每次50 mg，2次/d）后不再调整；而目标心率组则以目标心率诊室测量日间静息心率(55～60)次/min为导向，逐步滴定至最大耐受剂量。比较两组患者在用药后的心功能情况，评价指标包括纽约心功能分级、6分钟步行试验(6MWT)以及超声心动图相关指标。
        结果  与本组治疗前相比，两组患者治疗后超声心动图指标左室舒张末期内径（LVEDD），左室射血分数（LVEF值）以及6MWT结果均有显著改善（P<0.05）。目标心率组的LVEDD显著低于目标剂量组（P<0.01），而LVEF值显著高于目标剂量组（P<0.01）。目标心率组患者6MWT结果显著高于目标剂量组（P<0.05）。目标剂量组患者治疗后，29例（58%）患者纽约心功能分级为Ⅱ级，21例（42%）为Ⅲ级；而目标心率组有39例（78%）纽约心功能分级为Ⅱ级，11例（22%）为Ⅲ级；两组比较差异有统计学意义（P<0.05）。
        结论  目标心率组根据目标心率调整倍他乐克剂量的疗效更好。

       

      Abstract:
        AIM  To investigate the therapeutic effect of adjusted betaloc dose based on target heart rate in the treatment of coronary heart disease.
        METHODS  A total of 100 patients with coronary heart disease admitted to our hospital from June 2018 to December 2019 were randomly divided into target dose group and target heart rate group, with 50 patients in each group. In addition to other fixed secondary prevention drugs for coronary heart disease, the dose of betaloc was added step by step to target dose (50 mg, bid) in target dose group, while the dose was adjusted to the maximum tolerance dose step by step guided by target heart rate (55-60 bpm) in target heart rate group. The cardiac function of the two groups was compared after drug administration. The evaluation criteria included New York cardiac function rating, 6-minute walking test and echocardiographic indicators.
        RESULTS  Compared with those before treatment, the results of echocardiography (LVEDD, LVEF) and 6-minute walking test were significantly improved in both groups after treatment (P<0.05). The LVEDD in target heart rate group was significantly lower than that in target dose group (P<0.01), while the LVEF value target heart rate group was significantly higher than that in target dose group (P<0.01). The 6-minute walking test results of patients in target heart rate group were significantly higher than those in target dose group (P<0.05). After treatment, statistically significant difference was observed by New York heart function classification between target dose group ( class Ⅱ: 29 cases, 58% ; class Ⅲ: 21cases, 42%) and target heart rate group (class Ⅱ: 39 cases, 78% ; class Ⅲ:11 cases, 22%)
        CONCLUSION  The target heart rate group is more effective in the treatment of coronary heart disease.

       

      • HTML全文
      • 参考文献(15)
      • 相关文章
      • 施引文献
    • 资源附件(0)

    /

    返回文章
    返回